Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 50.1% in April

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 181,900 shares, an increase of 50.1% from the March 31st total of 121,200 shares. Based on an average daily trading volume, of 78,700 shares, the short-interest ratio is presently 2.3 days. Approximately 1.3% of the shares of the stock are short sold.

Gyre Therapeutics Stock Down 4.0 %

Shares of GYRE traded down $0.68 during mid-day trading on Monday, reaching $16.43. The company had a trading volume of 36,060 shares, compared to its average volume of 82,941. Gyre Therapeutics has a twelve month low of $3.00 and a twelve month high of $30.40. The stock’s 50-day moving average price is $17.67. The stock has a market cap of $1.40 billion, a P/E ratio of -0.79 and a beta of 2.11.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.